IP Library Granted Patent US 12,071,433
Granted Patent B2
US 12,071,433 · App. 18/377,606 · Granted Aug 27, 2024

HMOX1 inducers

Inventors: Margaret Biddle (Cambridge, MA); Arthur Kluge (Lincoln, MA); Sanjita Sasmal (Bangalore, IN); Bharat Lagu (Acton, MA); Xinyuan Wu (Chestnut Hill, MA); Takashi Ogiyama (Ibaraki, JP); Eric Bell (Somerville, MA)
Assignee: Astellas Engineered Small Molecules US, Incorporated
C07D413/14A61P9/08C07D403/12C07D413/12C07D417/12C07D417/14C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,071,433
App. No.
18/377,606
Granted
Aug 27, 2024
Kind
B2
Abstract

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

Claims (19)

1. A compound represented by structural formula (III-B):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is —C(═O)NH((C 1 -C 4 )hydroxyalkoxy(C 1 -C 4 )alkyl), —C(═O)NH(hydroxy(C 1 -C 4 )alkyl), —C(═O)NH(methoxy(C 1 -C 4 )alkyl), or —C(═O)NH(hydroxy(C 1 -C 4 )alkoxy); and

R 2 is OCH 2 CH 2 OCH 3 .

2. A compound represented by structural formula (III-B):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is —C(═O)NH(C 1 -C 4 )alkyl optionally substituted with —OH, —NH 2 , —(C 1 -C 4 )-alkoxy, or —(C 1 -C 4 )hydroxyalkoxy, and

R 2 is OCH 2 CH 2 OCH 3 .

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein

R 1 is —C(═O)NH(C 1 -C 4 )alkyl substituted with —(C 1 -C 4 )-alkoxy, and

R 2 is OCH 2 CH 2 OCH 3 .

4. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

5. The compound, or a pharmaceutically acceptable salt thereof, of claim 4 , wherein the compound is

6. The compound, or a pharmaceutically acceptable salt thereof, of claim 4 , wherein the compound is

7. The compound, or a pharmaceutically acceptable salt thereof, of claim 4 , wherein the compound is

8. The compound, or a pharmaceutically acceptable salt thereof, of claim 4 , wherein the compound is

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and the compound of claim 2 , or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and the compound of claim 4 , or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF NAME Recorded Jul 10, 2024
From: MITOBRIDGE, INC.
To: ASTELLAS ENGINEERED SMALL MOLECULES US, INCORPORATED
Reel/Frame 068274/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2023
From: OGIYAMA, TAKASHI
To: ASTELLAS PHARMA, INC.
Reel/Frame 065435/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2023
From: BIDDLE, MARGARET; KLUGE, ARTHUR; SASMAL, SANJITA; LAGU, BHARAT; WU, XINYUAN; BELL, ERIC
To: MITOBRIDGE, INC.
Reel/Frame 065435/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2023
From: ASTELLAS PHARMA INC.
To: MITOBRIDGE, INC.
Reel/Frame 065435/0252 →
Continuity (4)
Continuation 17602584
Provisional Application 62932629 · Nov 8, 2019
Provisional Application 62833031 · Apr 12, 2019
Related Publication 20240051952A1 · Feb 15, 2024